Shereen Ezzat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10615152/publications.pdf

Version: 2024-02-01

259 papers	14,495 citations	18436 62 h-index	24915 109 g-index
301 all docs	301 docs citations	301 times ranked	11335 citing authors

#	Article	IF	Citations
1	The prevalence of pituitary adenomas. Cancer, 2004, 101, 613-619.	2.0	1,126
2	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 2006, 6, 292-306.	12.8	797
3	Thyroid Incidentalomas. Archives of Internal Medicine, 1994, 154, 1838.	4.3	427
4	The pathogenesis of pituitary tumours. Nature Reviews Cancer, 2002, 2, 836-849.	12.8	327
5	Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma. Modern Pathology, 2001, 14, 338-342.	2.9	298
6	Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. Thyroid, 2009, 19, 451-457.	2.4	296
7	The Cytogenesis and Pathogenesis of Pituitary Adenomas*. Endocrine Reviews, 1998, 19, 798-827.	8.9	285
8	Octreotide Treatment of Acromegaly. Annals of Internal Medicine, 1992, 117, 711-718.	2.0	246
9	Distinct MultipleRET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4116-4122.	1.8	242
10	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	5.2	227
11	The Pathogenesis of Pituitary Tumors. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 97-126.	9.6	225
12	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathkeâ€™s Cleft Cyst, and Arachnoid Cyst. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3972-3982.	1.8	221
13	The Spectrum and Significance of Primary Hypophysitis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1048-1053.	1.8	182
14	Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2187-2190.	1.8	169
15	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
16	The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6290-6295.	1.8	165
17	The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults. Endocrine Reviews, 2006, 27, 287-317.	8.9	159
18	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2002, 109, 69-78.	3.9	155

#	Article	IF	Citations
19	Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 5-9.	1.8	150
20	A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clinical Endocrinology, 2008, 69, 479-490.	1.2	143
21	Are Patients with Acromegaly at Increased Risk forNeoplasiaÂ¿*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 245-249.	1.8	134
22	Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis. Thyroid, 2007, 17, 1277-1288.	2.4	132
23	The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis. Cancer Research, 2008, 68, 8104-8112.	0.4	127
24	Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1814-1818.	1.8	126
25	A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and longâ€acting octreotide in patients with acromegaly. Clinical Endocrinology, 2009, 71, 549-557.	1.2	126
26	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1745-1751.	1.8	123
27	Biomarkers of aggressive pituitary adenomas. Journal of Molecular Endocrinology, 2012, 49, R69-R78.	1.1	123
28	Myostatin Is a Skeletal Muscle Target of Growth Hormone Anabolic Action. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5490-5496.	1.8	120
29	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1160-1166.	1.8	116
30	Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma. Endocrinology, 2005, 146, 1145-1153.	1.4	115
31	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Modern Pathology, 2016, 29, 131-142.	2.9	114
32	Clonality of Thyroid Nodules in Sporadic Goiter. Diagnostic Molecular Pathology, 1995, 4, 113-121.	2.1	113
33	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 878-882.	1.8	111
34	Acromegaly: Re-thinking the cancer risk. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 41-58.	2.6	108
35	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. Journal of Clinical Medicine, 2018, 7, 280.	1.0	104
36	Prevalence of Activating ras Mutations in Morphologically Characterized Thyroid Nodules. Thyroid, 1996, 6, 409-416.	2.4	103

#	Article	IF	Citations
37	In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology, 1995, 133, 686-690.	1.9	100
38	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 340-352.	0.4	99
39	Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4570-4577.	1.8	94
40	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly. Endocrine Practice, 2004, 10, 213-225.	1.1	92
41	Inhibition of the Sodium Potassium Adenosine Triphosphatase Pump Sensitizes Cancer Cells to Anoikis and Prevents Distant Tumor Formation. Cancer Research, 2009, 69, 2739-2747.	0.4	90
42	Oncogene profile of papillary thyroid carcinoma. Surgery, 1999, 125, 46-52.	1.0	86
43	Cyclin D1 Protein Expression Predicts Metastatic Behavior in Thyroid Papillary Microcarcinomas But Is Not Associated with Gene Amplification. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1810-1813.	1.8	86
44	Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia. Molecular Endocrinology, 2004, 18, 2543-2552.	3.7	86
45	Mechanisms of Disease: the pathogenesis of pituitary tumors. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 220-230.	2.9	85
46	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. British Journal of Cancer, 2019, 120, 1113-1119.	2.9	83
47	Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways. American Journal of Pathology, 2002, 160, 511-519.	1.9	80
48	Colon Polyps in Acromegaly. Annals of Internal Medicine, 1991, 114, 754-755.	2.0	79
49	Ikaros Isoforms in Human Pituitary Tumors. American Journal of Pathology, 2003, 163, 1177-1184.	1.9	78
50	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treatment Reviews, 2016, 47, 32-45.	3.4	74
51	Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathology, 2003, 14, 183-191.	5.2	73
52	Improved Diagnostic Accuracy of Inferior Petrosal Sinus Sampling over Imaging for Localizing Pituitary Pathology in Patients with Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2291-2295.	1.8	72
53	Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1904-1911.	1.8	72
54	Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review. Thyroid, 2010, 20, 1129-1138.	2.4	71

#	Article	IF	Citations
55	Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia. Clinical Cancer Research, 2008, 14, 1984-1996.	3.2	70
56	Effect of octreotide on glucose tolerance in acromegaly. European Journal of Endocrinology, 1994, 130, 581-586.	1.9	69
57	A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clinical Endocrinology, 2008, 68, 610-617.	1.2	69
58	Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells. American Journal of Pathology, 2007, 170, 1618-1628.	1.9	68
59	Cancer-Related Worry in Canadian Thyroid Cancer Survivors. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 977-985.	1.8	68
60	A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior. Clinical Cancer Research, 2011, 17, 2385-2394.	3.2	67
61	Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression. Cancer Research, 2007, 67, 5461-5470.	0.4	65
62	TheMEN-1Gene Is Rarely Down-Regulated in Pituitary Adenomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3210-3212.	1.8	64
63	A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors. Cancer Research, 2007, 67, 7505-7511.	0.4	64
64	Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clinical Endocrinology, 2012, 76, 264-271.	1.2	64
65	Evidence for Growth Hormone (GH) Autoregulation in Pituitary Somatotrophs in GH Antagonist-Transgenic Mice and GH Receptor-Deficient Mice. American Journal of Pathology, 2000, 156, 1009-1015.	1.9	61
66	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocrine-Related Cancer, 2014, 21, R331-R344.	1.6	61
67	The Impact of Thyroid Cancer and Post-Surgical Radioactive Iodine Treatment on the Lives of Thyroid Cancer Survivors: A Qualitative Study. PLoS ONE, 2009, 4, e4191.	1.1	61
68	Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocrine Pathology, 1995, 6, 125-134.	5.2	60
69	The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis. PLoS Genetics, 2011, 7, e1002400.	1.5	59
70	Vitamin D3 Administration Induces Nuclear p27 Accumulation, Restores Differentiation, and Reduces Tumor Burden in a Mouse Model of Metastatic Follicular Thyroid Cancer. Endocrinology, 2004, 145, 5840-5846.	1.4	58
71	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clinical Cancer Research, 2005, 11, 1336-41.	3.2	57
72	Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 828.	1.7	55

#	Article	IF	Citations
73	The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production. Molecular Endocrinology, 2001, 15, 589-599.	3.7	54
74	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood, 2007, 110, 4047-4054.	0.6	54
75	Inhibition of the Sodium/Potassium ATPase Impairs N-Glycan Expression and Function. Cancer Research, 2008, 68, 6688-6697.	0.4	54
76	The Role of Hormones, Growth Factors and Their Receptors in Pituitary Tumorigenesis. Brain Pathology, 2001, 11, 356-370.	2.1	53
77	A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. Thyroid, 2018, 28, 1662-1673.	2.4	53
78	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. Archives of Pathology and Laboratory Medicine, 2014, 138, 182-188.	1.2	52
79	Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Molecular Endocrinology, 2006, 20, 2965-2975.	3.7	49
80	Pancreatic Endocrine Pathology in von Hippelâ€“Lindau Disease: An Expanding Spectrum of Lesions. Endocrine Pathology, 2004, 15, 141-148.	5.2	48
81	Cushingâ€™s Syndrome from an ectopic pituitary adenoma with peliosis: A histological, immunohistochemical, and ultrastructural study and review of the literature. Endocrine Pathology, 1997, 8, 65-74.	5.2	47
82	The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 4713-4720.	3.2	47
83	A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer. Thyroid, 2020, 30, 999-1007.	2.4	47
84	Diagnosis and management of hyperprolactinemia. Cmaj, 2003, 169, 575-81.	0.9	47
85	OCTREOTIDE STIMULATES INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1 (IGFBP-1) LEVELS IN ACROMEGALY. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 441-443.	1.8	46
86	Psychological Features of Acromegaly. Psychotherapy and Psychosomatics, 1998, 67, 147-153.	4.0	46
87	Molecular determinants of pituitary cytodifferentiation. , 1999, 1, 159-168.		46
88	1Î±,25-Dihydroxyvitamin D3 Targets PTEN-Dependent Fibronectin Expression to Restore Thyroid Cancer Cell Adhesiveness. Molecular Endocrinology, 2005, 19, 2349-2357.	3.7	46
89	Pituitary Tumor AP-2Î± Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4. Journal of Biological Chemistry, 2003, 278, 19597-19602.	1.6	45
90	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. Cancer Research, 2012, 72, 5683-5691.	0.4	45

#	Article	IF	Citations
91	An essential role for the hematopoietic transcription factor Ikaros in hypothalamicâ€“pituitary-mediated somatic growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2214-2219.	3.3	44
92	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Modern Pathology, 2021, 34, 1634-1650.	2.9	44
93	Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clinical Endocrinology, 2001, 55, 549-556.	1.2	43
94	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. Endocrine Pathology, 2019, 30, 118-127.	5.2	43
95	Molecular Basis of Pituitary Development and Cytogenesis. , 2004, 32, 1-19.		42
96	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Review of Endocrinology and Metabolism, 2016, 11, 149-162.	1.2	42
97	The Clinicopathological Spectrum of Acromegaly. Journal of Clinical Medicine, 2019, 8, 1962.	1.0	42
98	The câ€•erb Bâ€2/ neu protoâ€oncogene in human pituitary tumours. Clinical Endocrinology, 1997, 46, 599-606.	1.2	41
99	Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells. Molecular Endocrinology, 2006, 20, 2976-2986.	3.7	41
100	Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3610-3617.	1.8	41
101	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. Molecular Endocrinology, 2002, 16, 1069-1078.	3.7	40
102	The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility. Molecular Endocrinology, 2005, 19, 1004-1011.	3.7	40
103	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Human Pathology, 2007, 38, 1810-1818.	1.1	40
104	Growth Patterns of Pituitary Adenomas and Histopathological Correlates. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1330-1338.	1.8	40
105	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	39
106	Genetics and Proteomics of Pituitary Tumors. Endocrine, 2005, 28, 043-048.	2.2	38
107	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 727-732.	1.4	38
108	Pituitary acromegaly: not one disease. Endocrine-Related Cancer, 2017, 24, C1-C4.	1.6	37

#	Article	IF	Citations
109	Autoimmune Hypophysitis. Trends in Endocrinology and Metabolism, 1997, 8, 74-80.	3.1	36
110	A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 2001, 287, 60-65.	1.0	35
111	Ikaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	3.9	35
112	Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells. Brain Pathology, 2002, 12, 412-419.	2.1	34
113	Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clinical Endocrinology, 2013, 79, 79-85.	1.2	34
114	Predictive Markers for Postsurgical Medical Management of Acromegaly: A Systematic Review and Consensus Treatment Guideline. Endocrine Practice, 2019, 25, 379-393.	1.1	34
115	Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. Cancer, 1993, 71, 66-70.	2.0	33
116	Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 640-646.	1.2	33
117	AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas. Endocrine Pathology, 2007, 18, 76-78.	5.2	32
118	Histone-Acetylated Control of Fibroblast Growth Factor Receptor 2 Intron 2 Polymorphisms and Isoform Splicing in Breast Cancer. Molecular Endocrinology, 2009, 23, 1397-1405.	3.7	30
119	The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas. Endocrine Pathology, 2013, 24, 191-198.	5.2	30
120	Exercise Training Benefits Growth Hormone (GH)-Deficient Adults in the Absence or Presence of GH Treatment. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5734-5738.	1.8	29
121	Hormone profiling, WHO 2010 grading, and AJCC / UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Medicine, 2013, 2, 701-711.	1.3	29
122	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. , 0, .		29
123	Epigenetic Control in Pituitary Tumors. Endocrine Journal, 2008, 55, 951-957.	0.7	28
124	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippelâ€“Lindau disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 593-597.	1.4	28
125	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocrine Pathology, 2018, 29, 332-338.	5.2	28
126	Ikaros Modulates Cholesterol Uptake: A Link between Tumor Suppression and Differentiation. Cancer Research, 2008, 68, 3715-3723.	0.4	27

#	Article	IF	Citations
127	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. Molecular and Cellular Endocrinology, 2018, 469, 70-76.	1.6	27
128	Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clinical Endocrinology, 2002, 56, 351-358.	1.2	26
129	Epigenetic Dysregulation in Thyroid Neoplasia. Endocrinology and Metabolism Clinics of North America, 2008, 37, 389-400.	1.2	26
130	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses. American Journal of Surgical Pathology, 2017, 41, 525-534.	2.1	26
131	Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors. PLoS ONE, 2013, 8, e61538.	1.1	26
132	Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E494-E503.	1.8	25
133	FGFR2 Isoforms Support Epithelialâ€“Stromal Interactions in Thyroid Cancer Progression. Cancer Research, 2012, 72, 2017-2027.	0.4	25
134	The Clinicopathological Spectrum of Parathyroid Carcinoma. Frontiers in Endocrinology, 2019, 10, 731.	1.5	25
135	Management of Small Bowel Neuroendocrine Tumors. Cancers, 2019, 11, 1395.	1.7	25
136	Persistent Posttreatment Fatigue in Thyroid Cancer Survivors. Endocrinology and Metabolism Clinics of North America, 2014, 43, 475-494.	1.2	24
137	The epigenetic landscape of differentiated thyroid cancer. Molecular and Cellular Endocrinology, 2018, 469, 3-10.	1.6	24
138	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. Endocrine Pathology, 2019, 30, 201-218.	5.2	24
139	Hypothalamic Vasopressin-Producing Tumors. American Journal of Surgical Pathology, 2019, 43, 251-260.	2.1	24
140	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. Clinical Endocrinology, 2001, 55, 135-140.	1.2	23
141	Longitudinal Assessment of Economic Burden and Clinical Outcomes in Acromegaly. Endocrine Practice, 2001, 7, 170-180.	1.1	23
142	CtBP1 Interacts with Ikaros and Modulates Pituitary Tumor Cell Survival and Response to Hypoxia. Molecular Endocrinology, 2012, 26, 447-457.	3.7	23
143	The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF-ÎºB Signaling. Molecular and Cellular Biology, 2012, 32, 4662-4673.	1.1	23
144	The Role of Diabetes in Acromegaly Associated Neoplasia. PLoS ONE, 2015, 10, e0127276.	1.1	23

#	Article	IF	Citations
145	A Systematic Review and Meta-Analysis of Patient Preferences for Combination Thyroid Hormone Treatment for Hypothyroidism. Frontiers in Endocrinology, 2019, 10, 477.	1.5	23
146	Living with Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 753-760.	1.2	22
147	ACROMEGALY. Endocrinology and Metabolism Clinics of North America, 1997, 26, 703-723.	1.2	22
148	The Cost of Medical Care for the Acromegalic Patient. Neuroendocrinology, 2006, 83, 139-144.	1.2	22
149	A prospective multicenter octreotide dose response study in the treatment of acromegaly. Journal of Endocrinological Investigation, 1995, 18, 364-369.	1.8	20
150	Cytoplasmic staining oferbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clinical Endocrinology, 1998, 49, 629-637.	1.2	20
151	Chromatin remodeling and histone modifications in pituitary tumors. Molecular and Cellular Endocrinology, 2010, 326, 66-70.	1.6	20
152	Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage. Clinical Cancer Research, 2004, 10, 6750-6758.	3.2	19
153	Ikaros Is Regulated through Multiple Histone Modifications and Deoxyribonucleic Acid Methylation in the Pituitary. Molecular Endocrinology, 2007, 21, 1205-1215.	3.7	19
154	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. Journal of Molecular Endocrinology, 2008, 41, 45-51.	1.1	19
155	Basis for Physician Recommendations for Adjuvant Radioiodine Therapy in Early-Stage Thyroid Carcinoma: Principal Findings of the Canadian-American Thyroid Cancer Survey. Endocrine Practice, 2008, 14, 175-184.	1.1	19
156	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Frontiers in Endocrinology, 2018, 9, 641.	1.5	19
157	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocrine-Related Cancer, 2009, 16, 455-466.	1.6	18
158	FGFR4 Polymorphic Variants Modulate Phenotypic Features of Cushing Disease. Molecular Endocrinology, 2014, 28, 525-533.	3.7	18
159	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. Annals of Surgical Oncology, 2019, 26, 2533-2539.	0.7	18
160	Regional Differences in Opinions on Adjuvant Radioactive Iodine Treatment of Thyroid Carcinoma within Canada and the United States. Thyroid, 2007, 17, 1235-1242.	2.4	17
161	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. Modern Pathology, 2014, 27, 1050-1062.	2.9	17
162	Unmet Information Needs of Low-Risk Thyroid Cancer Survivors. Thyroid, 2016, 26, 474-475.	2.4	17

#	Article	IF	Citations
163	A Quantitative Analysis Examining Patients' Choice of Active Surveillance or Surgery for Managing Low-Risk Papillary Thyroid Cancer. Thyroid, 2022, 32, 255-262.	2.4	17
164	Medical management of pituitary adenomas: structural and ultrastructural changes. Pituitary, 2002, 5, 133-139.	1.6	16
165	Management of Lesions of the Pituitary Stalk and Hypothalamus. , 2003, 13, 38-51.		16
166	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. Experimental Neurology, 2008, 211, 107-114.	2.0	16
167	Functional Cardiac Paraganglioma Associated with a Rare SDHC Mutation. Endocrine Pathology, 2014, 25, 315-320.	5.2	16
168	Comprehensive characterization of a Canadian cohort of von Hippelâ€Lindau disease patients. Clinical Genetics, 2019, 96, 461-467.	1.0	16
169	Circulating and synovial levels of IGF-I, cytokines, physical function and anthropometry differ in women awaiting total knee arthroplasty when compared to men. Journal of Orthopaedic Research, 2005, 23, 397-405.	1.2	15
170	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer - a randomized controlled trial. Trials, 2010, 11, 81.	0.7	15
171	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. Endocrine Practice, 2014, 20, e145-e150.	1.1	15
172	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 2254.	1.0	15
173	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 3-16.	5.2	15
174	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. , 0, .		15
175	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. Oncotarget, 2016, 7, 19948-19959.	0.8	15
176	Growth Hormone Treatment Improves Peripheral Muscle Oxygen Extraction-Utilization during Exercise in Patients with Human Immunodeficiency Virus-Associated Wasting: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5124-5131.	1.8	14
177	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. Laboratory Investigation, 2004, 84, 1571-1580.	1.7	14
178	Complex Endocrinopathies in MEN-1: Diagnostic Dilemmas in Endocrine Oncology. Endocrine Pathology, 2007, 18, 37-41.	5.2	14
179	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. Laboratory Investigation, 2011, 91, 147-156.	1.7	14
180	Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 4-17.	0.1	14

#	Article	IF	Citations
181	Thyroid cancer patient perceptions of radioactive iodine treatment choice: Followâ€up from a decisionâ€aid randomized trial. Cancer, 2015, 121, 3717-3726.	2.0	14
182	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. Endocrine Pathology, 2016, 27, 97-103.	5.2	14
183	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. Oncotarget, 2017, 8, 3481-3494.	0.8	14
184	Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. Leukemia Research, 2008, 32, 1480-1482.	0.4	13
185	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	2.1	13
186	A Systematic Review of Randomized Controlled Trials for Management of Persistent Post-Treatment Fatigue in Thyroid Cancer Survivors. Thyroid, 2015, 25, 198-210.	2.4	13
187	Continuous Versus Intermittent Subcutaneous Infusion of Octreotide in the Treatment of Acromegaly. Journal of Clinical Pharmacology, 1995, 35, 59-71.	1.0	12
188	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. American Journal of Physiology - Endocrinology and Metabolism, 2002, 283, E490-E495.	1.8	12
189	Dopaminergic Resistant Prolactinomas in the Peripubertal Population. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 951-3.	0.4	12
190	Controversies in Papillary Microcarcinoma of the Thyroid. Endocrine Pathology, 2003, 14, 183-192.	5.2	12
191	Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly. PLoS ONE, 2013, 8, e73543.	1.1	11
192	Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. OncoTargets and Therapy, 2017, Volume 10, 5459-5462.	1.0	11
193	Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis. Journal of Cancer Survivorship, 2019, 13, 231-243.	1.5	11
194	Genomic Approaches to Problems in Pituitary Neoplasia. Endocrine Pathology, 2014, 25, 209-213.	5.2	10
195	A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto women. BMC Public Health, 2016, 16, 950.	1.2	10
196	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. World Neurosurgery, 2021, 146, e341-e350.	0.7	10
197	Endocrine applications of the somatostatin analogue octreotide (SandostatinÂ®). Metabolism: Clinical and Experimental, 1992, 41, 34-38.	1.5	9
198	Microadenomatosis of the Pancreas in von Hippel-Lindau Disease. American Journal of Surgical Pathology, 2006, 30, 1630.	2.1	9

#	Article	IF	Citations
199	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. Thyroid, 2013, 23, 246-247.	2.4	9
200	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. Endocrine Pathology, 2018, 29, 15-20.	5.2	9
201	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. Endocrine Pathology, 2021, 32, 415-417.	5.2	9
202	Canadian consensus statement on the management of radioactive iodineâ€“resistant differentiated thyroid cancer. Oral Oncology, 2021, 121, 105477.	0.8	9
203	Pituitary Tumor Pathogenesisâ€”The Hunt for Novel Candidate Genes Continues. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5116-5118.	1.8	8
204	Comparison of Body Composition Assessment Methods in Patients with Human Immunodeficiency Virus-Associated Wasting Receiving Growth Hormone. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2952-2959.	1.8	8
205	AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease. Endocrine Practice, 2014, 20, 608-616.	1.1	8
206	Concerns of low-risk thyroid cancer survivors. Acta OncolÃ³gica, 2016, 55, 1252-1253.	0.8	8
207	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. Endocrine-Related Cancer, 2016, 23, 445-456.	1.6	8
208	Canadian consensus guidelines for the diagnosis and management of acromegaly. Clinical and Investigative Medicine, 2006, 29, 29-39.	0.3	8
209	Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance. Insights Into Imaging, 2021, 12, 130.	1.6	7
210	Exploring the relationship between patientsâ€™ information preference style and knowledge acquisition process in a computerized patient decision aid randomized controlled trial. BMC Medical Informatics and Decision Making, 2015, 15, 48.	1.5	6
211	Primary mediastinal paraganglioma associated with a familial variant in the succinate dehydrogenase B subunit gene. Journal of Surgical Oncology, 2018, 117, 160-162.	0.8	6
212	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. Frontiers in Endocrinology, 2021, 12, 620005.	1.5	6
213	Autoimmune Hypophysitis. , 1999, , 337-348.		6
214	A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. Clinical and Investigative Medicine, 2009, 32, 265.	0.3	6
215	Managing newly diagnosed thyroid cancer. Cmaj, 2014, 186, 269-275.	0.9	5
216	Exploring the Life Impact of Treated Low-Risk Thyroid Cancer. Endocrine Practice, 2016, 22, 513-514.	1.1	5

#	Article	IF	Citations
217	Symptom burden in adults with thyroid cancer. Psycho-Oncology, 2018, 27, 2517-2519.	1.0	5
218	[13C]NMR studies of the effect of the somatostatin analogue octreotide on hepatic glycogenesis and glycogenolysis. Peptides, 1994, 15, 1223-1227.	1.2	4
219	Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. Trials, 2015, 16, 302.	0.7	4
220	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. Molecular and Cellular Endocrinology, 2017, 439, 126-132.	1.6	4
221	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. Molecular and Cellular Endocrinology, 2018, 461, 188-193.	1.6	4
222	A large and aggressive fibromatosis in the axilla: a rare case report and review of the literature. OncoTargets and Therapy, 2018, Volume 11, 3179-3184.	1.0	4
223	Clinical Predictors of Advanced Sellar Masses. Endocrine Practice, 2007, 13, 609-614.	1.1	3
224	GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules. Endocrine Pathology, 2010, 21, 250-252.	5.2	3
225	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. , 2015, , 125-139.		3
226	Endoscopic Treatment of Sellar Arachnoid Cysts via a Simple Cyst-Opening Technique: Long-Term Outcomes From a Single Center. World Neurosurgery, 2022, 161, e625-e634.	0.7	3
227	Clinicopathological variations in cushingâ€™s syndrome. Endocrine Pathology, 1999, 10, 165-171.	5.2	2
228	Temporal Trends in Thyroid Cancer Incidence in Californiaâ€”Letter. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2609-2609.	1.1	2
229	Re: Quality of life and symptom impact of thyroid cancer: A cross-sectional survey of Canadian patients. Surgery, 2019, 166, 948-949.	1.0	2
230	Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164.	1.1	2
231	Hypothalamic hormone-producing tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 181, 67-74.	1.0	2
232	The Diagnosis of Neuroendocrine Neoplasms. , 2021, , 15-27.		2
233	The Classification of Pituitary Tumors: An Update. Seminars in Neurosurgery, 2001, 12, 273-288.	0.0	1
234	Growth Hormone Deficiency and Physical Function. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1839-1846.	1.8	1

#	Article	IF	Citations
235	Pharmacological approach to the treatment of acromegaly. Neurosurgical Focus, 2004, 16, 1-4.	1.0	1
236	Lessons learned from thyroglobulin concentrations after total thyroidectomy and radioactive iodine ablation for differentiated thyroid cancer. Clinical Biochemistry, 2015, 48, 747-748.	0.8	1
237	Pancreatic Incidentalomas: Is it Net or Not?. Endocrine Practice, 2016, 22, 895-896.	1.1	1
238	Growth Factors and their Receptors in the Genesis and Treatment of Thyroid Cancer. Cancer Treatment and Research, 2005, 122, 121-130.	0.2	1
239	Targeted expression of a human pituitary tumorâ€“derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation, 2015, 125, 3303-3303.	3.9	1
240	CSCI DISTINGUISHED SCIENTIST LECTURE: Chromatin remodeling: The interface between extrinsic cues and the genetic code?. Clinical and Investigative Medicine, 2008, 31, 272.	0.3	1
241	Pharmacological options in the treatment of acromegaly. Current Opinion in Investigational Drugs, 2005, 6, 1023-7.	2.3	1
242	The Pathophysiology of Pituitary Tumors. Seminars in Neurosurgery, 2001, 12, 261-272.	0.0	0
243	Current views on pathogenesis of pituitary tumors. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 281-286.	0.6	0
244	Is autoimmune pituitary disease underdiagnosed?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 678-679.	2.9	0
245	Mechanisms of pituitary tumorigenesis. , 0, , 652-668.		0
246	Epigenetics of Pituitary Cell Growth and Survival. , 2014, , 101-110.		0
247	Thyroid Cancer Incidence and Endocrinologist Access: A Regional Data Analysis from Ontario, Canada. Endocrine Practice, 2016, 22, 642-643.	1.1	0
248	Molecular Pathogenesis of Pituitary Tumors. , 2017, , 165-175.		0
249	Pituitary Tumors; Diagnosis and Treatment. , 2018, , 257-257.		0
250	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. Contemporary Endocrinology, 2019, , 155-172.	0.3	0
251	Response to Miyauchi et al. re: â€œA Prospective Mixed-Methods Study of Decision Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancerâ€. Thyroid, 2020, 30, 1542-1543.	2.4	0
252	Epigenetics of Pituitary Cell Growth and Survival. , 2021, , 93-103.		0

#	Article	IF	Citations
253	Pathology of pituitary growth hormone excess. , 2021, , 17-37.		0
254	Pituitary Tumors, Molecular Pathogenesis. , 2004, , 681-686.		0
255	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. AACE Clinical Case Reports, 2018, 4, e289-e293.	0.4	0
256	Is Hypothalamic Oxytocin Dispensable for Parturition?. AACE Clinical Case Reports, 2018, 4, e437-e438.	0.4	0
257	Endoscopic Endonasal Surgery for Prolactinomas: Prognostic Factors for Disease Control and Management of Persistent Disease. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.4	0
258	A Novel Human Heterozygous SCP2 Mutation Leads to Alterations in Lipid Metabolism. FASEB Journal, 2022, 36, .	0.2	0
259	Is there a role for surgery after chemotherapy in recurrent/metastatic adrenal cortical cancer (ACC)?. Journal of Clinical Oncology, 2022, 40, 5092-5092.	0.8	0